DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Neurogenic bladder — screening already-approved drugs against its 10-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleNeurogenic bladder maps to a 10-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for neurogenic bladder is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
adrenoceptor beta 3 (ADRB3) — ADRB3 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet aledrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 9IJE · 2.34 Å · ligand L-EPINEPHRINE (ALE). Experimental structure, not a prediction.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Postgraduate Medicine · 1954 · 5 citations
The Neurogenic Bladder
AbstractNeurogenic bladder is a broad term embracing many disturbances in bladder function. Today there is an increased incidence of this disorder. It is important to differentiate the neurogenic bladder from organic bladder disease. Once a diagnosis has been established, a set pattern of treatment can be started. A patient having a neurogenic bladder must be considered a lifelong patient subject to many late complications.
European Journal of Pediatric Surgery · 1987 · 0 citations
Erfahrungen in der Diagnostik und Therapie neurogener Blasenentleerungsstörungen
AbstractToday extensive urodynamic investigations are indispensable for diagnosing and for an on-target treatment of neurogenic bladder dysfunction. Classifications and forms used according to functional aspects are explained. Possible treatment methods are commented in respect of own experiences, especially with regard to chemotherapy, intermittent catheterisation, transurethral electrostimulation, biofeedback therapy and supravesical urinary diversion.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
